AIM ImmunoTech Inc. ownership disclosure: three related reporting persons (Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC) filed a joint Schedule 13G describing potential beneficial ownership tied to a Securities Purchase Agreement executed May 20, 2026.
The filing states that 1,538,462 shares of Common Stock may be issuable to Intracoastal at closing, representing approximately 8.5% based on 16,505,501 shares outstanding as of May 20, 2026. It also discloses an Intracoastal Warrant for 3,076,924 shares subject to stockholder approval and a 4.99% exercise blocker. As of close of business on May 27, 2026, the filing reports the reporting persons may be deemed to beneficially own 0 shares.
Positive
None.
Negative
None.
Insights
Schedule 13G reports potential post-transaction ownership and warrant terms tied to a purchase agreement.
The filing lists 1,538,462 shares potentially issuable to Intracoastal at closing and an Intracoastal Warrant exercisable for 3,076,924 shares only after stockholder approval. It cites 16,505,501 shares outstanding as of May 20, 2026.
Key dependency is the stockholder approval that conditions exercisability; the warrant includes a 4.99% beneficial-ownership blocker. Subsequent filings or the issuer's Form 8-K may show closing results or shareholder vote outcomes.
Filing frames ownership as conditional and clarifies voting/dispositive powers are zero.
The joint filing attributes no current sole or shared voting or dispositive power to the reporting persons and states beneficial ownership calculations are conditional on the SPA closing and stockholder approval for warrant-related shares.
Legal effect centers on timing and the blocker provision; whether warrants become exercisable depends on a stockholder approval event referenced verbatim in the text.
Key Figures
Potential shares to be issued:1,538,462 sharesOutstanding shares (as reported):16,505,501 sharesIntracoastal Warrant:3,076,924 shares+3 more
6 metrics
Potential shares to be issued1,538,462 sharesissuable to Intracoastal at SPA closing
Outstanding shares (as reported)16,505,501 sharesoutstanding as of May 20, 2026
Intracoastal Warrant3,076,924 sharesshares issuable upon exercise of Intracoastal Warrant (subject to approval)
Reported ownership percentage8.5%approximate percentage if 1,538,462 shares issued (based on May 20, 2026 outstanding)
Beneficial-ownership blocker4.99%exercise blocker in Intracoastal Warrant
Beneficial ownership as of May 27, 20260 sharesreporting persons may be deemed to beneficially own no shares at close of business May 27, 2026
"Immediately following the execution of the Securities Purchase Agreement with the Issuer on May 20, 2026"
Intracoastal Warrantfinancial
"The foregoing excludes 3,076,924 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal"
Beneficial ownershipregulatory
"may have been deemed to have beneficial ownership of 1,538,462 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Blocker provisionlegal
"contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent ... of more than 4.99%"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
AIM ImmunoTech Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
00901B303
(CUSIP Number)
05/20/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00901B303
1
Names of Reporting Persons
Mitchell P. Kopin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
00901B303
1
Names of Reporting Persons
Daniel B. Asher
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
00901B303
1
Names of Reporting Persons
Intracoastal Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
AIM ImmunoTech Inc.
(b)
Address of issuer's principal executive offices:
2117 SW Highway 484, Ocala, Florida 34473
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)
Address or principal business office or, if none, residence:
The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.
(c)
Citizenship:
Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)
Title of class of securities:
Common stock, par value $0.001 per share
(e)
CUSIP Number(s):
00901B303
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
(i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on May 20, 2026 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on May 21, 2026), each of the Reporting Persons may have been deemed to have beneficial ownership of 1,538,462 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 8.5% of the Common Stock, based on (1) 16,505,501 shares of Common Stock outstanding as of May 20, 2026, as reported by the Issuer, plus (2) 1,538,462 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes 3,076,924 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (the "Intracoastal Warrant") because the Intracoastal Warrant is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Intracoastal Warrant (and the Intracoastal Warrant also contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock). Without such blocker provision (and assuming the Intracoastal Warrant was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 4,615,386 shares of Common Stock.
(ii) As of the close of business on May 27, 2026, each of the Reporting Persons may have been deemed to have beneficial ownership of no shares of Common Stock. The foregoing excludes 3,076,924 shares of Common Stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Intracoastal Warrant (and the Intracoastal Warrant also contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock). Without such blocker provision (and assuming the Intracoastal Warrant was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 3,076,924 shares of Common Stock.
(b)
Percent of class:
0.00%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What ownership stake does AIM ImmunoTech (AIM) disclose for Intracoastal in this filing?
The filing states 1,538,462 shares may be issued to Intracoastal at closing, reported as approximately 8.5% of Common Stock based on 16,505,501 shares outstanding as of May 20, 2026. This percentage is conditional on the SPA closing.
Are there additional shares tied to warrants in the Schedule 13G for AIM?
Yes. The filing discloses an Intracoastal Warrant exercisable for 3,076,924 shares, but exercisability is conditioned on stockholder approval of the issuance of underlying shares and subject to a 4.99% blocker provision.
Does the filing show the reporting persons currently control AIM ImmunoTech shares?
No. The filing reports 0 sole or shared voting and dispositive power and states that as of close of business on May 27, 2026 the reporting persons may be deemed to beneficially own 0 shares.
What conditional language affects the Intracoastal Warrant in the disclosure?
The warrant is not exercisable until the effective date of stockholder approval of the issuance of the shares issuable on exercise, and it contains a 4.99% beneficial-ownership blocker limiting exercise to avoid exceeding that threshold.
Who signed the joint Schedule 13G for AIM ImmunoTech?
The joint filing is signed by Mitchell P. Kopin and Daniel B. Asher, with Kopin also signing on behalf of Intracoastal Capital LLC as Manager, dated 05/27/2026.
